Literature DB >> 33384303

Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for μ-Opioid Receptor and Opioid-Like Behavioral Effects in Rats.

Samuel Obeng1, Jenny L Wilkerson1, Francisco León1, Morgan E Reeves1, Luis F Restrepo1, Lea R Gamez-Jimenez1, Avi Patel1, Anna E Pennington1, Victoria A Taylor1, Nicholas P Ho1, Tobias Braun1, John D Fortner1, Morgan L Crowley1, Morgan R Williamson1, Victoria L C Pallares1, Marco Mottinelli1, Carolina Lopera-Londoño1, Christopher R McCurdy1, Lance R McMahon1, Takato Hiranita2.   

Abstract

Relationships between µ-opioid receptor (MOR) efficacy and effects of mitragynine and 7-hydroxymitragynine are not fully established. We assessed in vitro binding affinity and efficacy and discriminative stimulus effects together with antinociception in rats. The binding affinities of mitragynine and 7-hydroxymitragynine at MOR (Ki values 77.9 and 709 nM, respectively) were higher than their binding affinities at κ-opioid receptor (KOR) or δ-opioid receptor (DOR). [35S]guanosine 5'-O-[γ-thio]triphosphate stimulation at MOR demonstrated that mitragynine was an antagonist, whereas 7-hydroxymitragynine was a partial agonist (Emax = 41.3%). In separate groups of rats discriminating either morphine (3.2 mg/kg) or mitragynine (32 mg/kg), mitragynine produced a maximum of 72.3% morphine-lever responding, and morphine produced a maximum of 65.4% mitragynine-lever responding. Other MOR agonists produced high percentages of drug-lever responding in the morphine and mitragynine discrimination assays: 7-hydroxymitragynine (99.7% and 98.1%, respectively), fentanyl (99.7% and 80.1%, respectively), buprenorphine (99.8% and 79.4%, respectively), and nalbuphine (99.4% and 98.3%, respectively). In the morphine and mitragynine discrimination assays, the KOR agonist U69,593 produced maximums of 72.3% and 22.3%, respectively, and the DOR agonist SNC 80 produced maximums of 34.3% and 23.0%, respectively. 7-Hydroxymitragynine produced antinociception; mitragynine did not. Naltrexone antagonized all of the effects of morphine and 7-hydroxymitragynine; naltrexone antagonized the discriminative stimulus effects of mitragynine but not its rate-decreasing effects. Mitragynine increased the potency of the morphine discrimination yet decreased morphine antinociception. Here we illustrate striking differences in MOR efficacy, with mitragynine having less than 7-hydroxymitragynine. SIGNIFICANCE STATEMENT: At human µ-opioid receptor (MOR) in vitro, mitragynine has low affinity and is an antagonist, whereas 7-hydroxymitragynine has 9-fold higher affinity than mitragynine and is an MOR partial agonist. In rats, intraperitoneal mitragynine exhibits a complex pharmacology including MOR agonism; 7-hydroxymitragynine has higher MOR potency and efficacy than mitragynine. These results are consistent with 7-hydroxymitragynine being a highly selective MOR agonist and with mitragynine having a complex pharmacology that combines low efficacy MOR agonism with activity at nonopioid receptors.
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33384303      PMCID: PMC7923387          DOI: 10.1124/jpet.120.000189

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  42 in total

1.  Attenuation of mu-opioid tolerance and cross-tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY235959 is related to tolerance and cross-tolerance magnitude.

Authors:  R M Allen; L A Dykstra
Journal:  J Pharmacol Exp Ther       Date:  2000-12       Impact factor: 4.030

2.  Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine.

Authors:  Scott E Hemby; Scot McIntosh; Francisco Leon; Stephen J Cutler; Christopher R McCurdy
Journal:  Addict Biol       Date:  2018-06-27       Impact factor: 4.280

3.  Some observations on the pharmacology of mitragynine.

Authors:  E Macko; J A Weisbach; B Douglas
Journal:  Arch Int Pharmacodyn Ther       Date:  1972

4.  Receptor-selective antagonism of opioid antinociception in female versus male rats.

Authors:  R M Craft; A H Tseng; D M McNiel; M S Furness; K C Rice
Journal:  Behav Pharmacol       Date:  2001-12       Impact factor: 2.293

5.  Abuse liability of mitragynine assessed with a self-administration procedure in rats.

Authors:  Kai Yue; Theresa A Kopajtic; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2018-07-23       Impact factor: 4.530

6.  Why does Coomassie Brilliant Blue R interact differently with different proteins? A partial answer.

Authors:  M Tal; A Silberstein; E Nusser
Journal:  J Biol Chem       Date:  1985-08-25       Impact factor: 5.157

7.  Lack of Specific Involvement of (+)-Naloxone and (+)-Naltrexone on the Reinforcing and Neurochemical Effects of Cocaine and Opioids.

Authors:  Gianluigi Tanda; Maddalena Mereu; Takato Hiranita; Juliana C Quarterman; Mark Coggiano; Jonathan L Katz
Journal:  Neuropsychopharmacology       Date:  2016-06-14       Impact factor: 7.853

8.  Evaluation of the interactions of mu and delta selective ligands with [3H]D-Ala2-D-Leu5-enkephalin binding to mouse brain membranes.

Authors:  R W Barrett; J L Vaught
Journal:  Life Sci       Date:  1983-12-12       Impact factor: 5.037

9.  Evaluating kratom alkaloids using PHASE.

Authors:  Christopher R Ellis; Rebecca Racz; Naomi L Kruhlak; Marlene T Kim; Alexey V Zakharov; Noel Southall; Edward G Hawkins; Keith Burkhart; David G Strauss; Lidiya Stavitskaya
Journal:  PLoS One       Date:  2020-03-03       Impact factor: 3.240

10.  Antinociceptive action of isolated mitragynine from Mitragyna Speciosa through activation of opioid receptor system.

Authors:  Abdul Rahman Shamima; Sharida Fakurazi; Mohamad Taufik Hidayat; Ithnin Hairuszah; Mohamad Aris Mohd Moklas; Palanisamy Arulselvan
Journal:  Int J Mol Sci       Date:  2012-09-12       Impact factor: 6.208

View more
  19 in total

1.  Oxidative Metabolism as a Modulator of Kratom's Biological Actions.

Authors:  Soumen Chakraborty; Rajendra Uprety; Samuel T Slocum; Takeshi Irie; Valerie Le Rouzic; Xiaohai Li; Lisa L Wilson; Brittany Scouller; Amy F Alder; Andrew C Kruegel; Michael Ansonoff; Andras Varadi; Shainnel O Eans; Amanda Hunkele; Abdullah Allaoa; Sanjay Kalra; Jin Xu; Ying Xian Pan; John Pintar; Bronwyn M Kivell; Gavril W Pasternak; Michael D Cameron; Jay P McLaughlin; Dalibor Sames; Susruta Majumdar
Journal:  J Med Chem       Date:  2021-11-16       Impact factor: 7.446

2.  The Lack of Contribution of 7-Hydroxymitragynine to the Antinociceptive Effects of Mitragynine in Mice: A Pharmacokinetic and Pharmacodynamic Study.

Authors:  Erin C Berthold; Shyam H Kamble; Kanumuri S Raju; Michelle A Kuntz; Alexandria S Senetra; Marco Mottinelli; Francisco León; Luis F Restrepo; Avi Patel; Nicholas P Ho; Takato Hiranita; Abhisheak Sharma; Lance R McMahon; Christopher R McCurdy
Journal:  Drug Metab Dispos       Date:  2021-11-10       Impact factor: 3.922

3.  Activity of Mitragyna speciosa ("Kratom") Alkaloids at Serotonin Receptors.

Authors:  Francisco León; Samuel Obeng; Marco Mottinelli; Yiming Chen; Tamara I King; Erin C Berthold; Shyam H Kamble; Luis F Restrepo; Avi Patel; Lea R Gamez-Jimenez; Carolina Lopera-Londoño; Takato Hiranita; Abhisheak Sharma; Aidan J Hampson; Clinton E Canal; Lance R McMahon; Christopher R McCurdy
Journal:  J Med Chem       Date:  2021-09-01       Impact factor: 8.039

4.  Associations of Lifetime Nonmedical Opioid, Methamphetamine, and Kratom Use within a Nationally Representative US Sample.

Authors:  Kirsten E Smith; Jeffrey M Rogers; Justin C Strickland
Journal:  J Psychoactive Drugs       Date:  2021-11-29

5.  Exploring the Chemistry of Alkaloids from Malaysian Mitragyna speciosa (Kratom) and the Role of Oxindoles on Human Opioid Receptors.

Authors:  Nelson Jeng-Yeou Chear; Francisco León; Abhisheak Sharma; Siva Rama Raju Kanumuri; Grant Zwolinski; Khalil A Abboud; Darshan Singh; Luis F Restrepo; Avi Patel; Takato Hiranita; Surash Ramanathan; Aidan J Hampson; Lance R McMahon; Christopher R McCurdy
Journal:  J Nat Prod       Date:  2021-02-26       Impact factor: 4.050

6.  Physiological dependence to mitragynine indicated by a rapid cross-dependence procedure with heroin-dependent mice.

Authors:  Kai Yue; Jonathan L Katz; Xiji Shu
Journal:  Psychopharmacology (Berl)       Date:  2022-02-02       Impact factor: 4.530

7.  Kratom pharmacology: Clues from planarians exposed to mitragynine.

Authors:  Sarah Uddin; Sonita Wiah; Tony Kim; Mia N Watson; Tyra Jennings; Scott M Rawls
Journal:  Physiol Behav       Date:  2021-06-17

8.  Therapeutic benefit with caveats?: Analyzing social media data to understand the complexities of kratom use.

Authors:  Kirsten E Smith; Jeffrey M Rogers; Destiny Schriefer; Oliver Grundmann
Journal:  Drug Alcohol Depend       Date:  2021-06-25       Impact factor: 4.852

9.  Kratom Alkaloids as Probes for Opioid Receptor Function: Pharmacological Characterization of Minor Indole and Oxindole Alkaloids from Kratom.

Authors:  Soumen Chakraborty; Rajendra Uprety; Amal E Daibani; Valerie L Rouzic; Amanda Hunkele; Kevin Appourchaux; Shainnel O Eans; Nitin Nuthikattu; Rahul Jilakara; Lisa Thammavong; Gavril W Pasternak; Ying-Xian Pan; Jay P McLaughlin; Tao Che; Susruta Majumdar
Journal:  ACS Chem Neurosci       Date:  2021-07-02       Impact factor: 5.780

10.  The use of hypercapnic conditions to assess opioid-induced respiratory depression in rats.

Authors:  Morgan L Crowley; Luis F Restrepo; Lea R Gamez-Jimenez; Avi Patel; Tobias Braun; Victoria L C Pallares; Nicholas P Ho; Morgan E Reeves; Christopher R McCurdy; Lance R McMahon; Takato Hiranita
Journal:  J Pharmacol Toxicol Methods       Date:  2021-07-07       Impact factor: 2.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.